Protocatechuic Acid Crystals for RSV Viral Envelope Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Respiratory Syncytial Virus (RSV) and other enveloped viruses lack effective methods beyond chemical interventions, as they are physically vulnerable and can be disrupted by physical means, such as protocatechuic acid crystals.
Innovation Solution
Administering protocatechuic acid crystals, which have sharp protrusions and a low pH, to physically disrupt the viral envelope of enveloped viruses, inhibiting their entry into host cells and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical treatments are used to treat enveloped viruses, then antiviral effect is achieved, but the physical vulnerability of the viral envelope is not utilized
Solution Approach 1:
The patent replaces chemical antiviral mechanisms with a physical mechanical disruption system. Crystals with sharp protrusions mechanically pierce and disrupt the viral envelope through physical contact, eliminating the need for chemical interactions to achieve antiviral effect.
Solution Approach 2:
The invention changes the mode of action from chemical to physical by altering the fundamental parameter of interaction. Instead of chemical bonds or reactions, the crystal's physical structure (sharp protrusions) provides mechanical disruption, changing the state of interaction from molecular to macroscopic physical force.
2Reliability
If physical disruption method is used to destroy viral envelope, then effectiveness against enveloped viruses is improved, but development of such physical treatment methods is limited
Solution Approach 1:
The crystal structure inherently provides the disruptive mechanism through its own physical properties. The sharp protrusions are intrinsic to the crystal form, requiring no additional manufacturing complexity or external mechanical systems to achieve the disruptive effect.
Solution Approach 2:
The patent transforms the physical state or form of the treatment agent to achieve effectiveness. By utilizing crystals with specific geometric properties (sharp protrusions) rather than amorphous materials, the physical disruption capability is inherently built into the material's structure.
3Duration of action of moving object
If multiple administration routes are used to provide prolonged antiviral effect, then treatment duration is extended, but complexity of administration system increases
Solution Approach 1:
The crystal-based treatment achieves prolonged antiviral effect through multiple administration routes (oral, intravenous, topical, inhalation) using the same fundamental mechanism. This universal applicability across different routes extends treatment duration without requiring different mechanisms or systems for each route.
Solution Approach 2:
The treatment agent serves itself across multiple administration routes through its inherent physical properties. The crystal structure provides consistent mechanical disruption regardless of how it is delivered to the body, eliminating the need for complex route-specific systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystals effectively inactivate enveloped viruses by physically disrupting their envelopes and inhibiting viral replication, providing a prolonged antiviral effect through various administration routes, including oral, intravenous, and topical applications.
Implementation Method 1
The physical nature of crystals can have an antimicrobial property independent or in conjunction with biochemical properties. Their many sharp edges have the potential to physically disrupt a microbe's soft lipoid envelope's integrity.
Implementation Method 2
The inactivation continues in that PCA has a low pH that further destroys the exposed RNA and or DNA.
Data Source
AI summary
In embodiments, a method of treating a disease or condition caused by Respiratory Syncytial Virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier.